1. Home
  2. GEVO vs ALDX Comparison

GEVO vs ALDX Comparison

Compare GEVO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$2.18

Market Cap

568.2M

Sector

Industrials

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$1.56

Market Cap

317.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEVO
ALDX
Founded
2005
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
568.2M
317.7M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
GEVO
ALDX
Price
$2.18
$1.56
Analyst Decision
Buy
Buy
Analyst Count
3
2
Target Price
$6.42
$5.50
AVG Volume (30 Days)
4.6M
6.2M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
58.82
40.43
EPS
N/A
N/A
Revenue
$711,000.00
N/A
Revenue This Year
$19.44
N/A
Revenue Next Year
$5.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.97
$1.07
52 Week High
$2.97
$6.18

Technical Indicators

Market Signals
Indicator
GEVO
ALDX
Relative Strength Index (RSI) 45.36 27.29
Support Level $1.94 $1.07
Resistance Level $2.19 $5.70
Average True Range (ATR) 0.18 0.26
MACD -0.03 -0.01
Stochastic Oscillator 1.24 37.70

Price Performance

Historical Comparison
GEVO
ALDX

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: